ERK-Dependent Downregulation of the Atypical Chemokine Receptor D6 Drives Tumor Aggressiveness in Kaposi Sarcoma

Benedetta Savino1,2, Nicoletta Caronni1,2, Achille Anselmo1, Fabio Pasqualini1, Elena Monica Borroni1,2, Gianluca Basso1, Giuseppe Celesti1, Luigi Laghi1, Athanasia Tourlaki4, Vinicio Boneschi4, Lucia Brambilla4, Manuela Nebuloni5, Gianluca Vago6, Alberto Mantovani1,2, Massimo Locati1,2, and Raffaella Bonecchi1,2

Abstract

D6 is an atypical chemokine receptor acting as a decoy and scavenger for inflammatory CC chemokines expressed in lymphatic endothelial cells. Here, we report that D6 is expressed in Kaposi sarcoma (KS), a tumor ontogenetically related to the lymphatic endothelium. Both in human tumors and in an experimental model, D6 expression levels were inversely correlated with tumor aggressiveness and increased infiltration of proangiogenic macrophages. Inhibition of monocyte recruitment reduced the growth of tumors, while adoptive transfer of wild-type, but not CCR2−/− macrophages, increased the growth rate of D6-competent neoplasms. In the KS model with the B-Raf V600E-activating mutation, inhibition of B-Raf or the downstream ERK pathway induced D6 expression; in progressing human KS tumors, the activation of ERK correlates with reduced levels of D6 expression. These results indicate that activation of the K-Ras–B-Raf–ERK pathway during KS progression downregulates D6 expression, which unleashes chemokine-mediated macrophage recruitment and their acquisition of an M2-like phenotype supporting angiogenesis and tumor growth. Combined targeting of CCR2 and the ERK pathway should be considered as a therapeutic option for patients with KS. Cancer Immunol Res; 2(7); 679–89. © 2014 AACR.

Introduction

Chemokines are a superfamily of inflammatory mediators supporting cell migration and leukocyte activation through a distinct family of class A G protein-coupled receptors (GPCR; refs. 1, 2). Besides these canonical receptors, which support chemotactic activity, there is a separate group of atypical chemokine receptors that do not directly mediate cell migration but are still involved in leukocyte recruitment as they participate in chemokine gradient formation by trapping, degrading, or transporting their ligands (3, 4). D6 is an atypical chemokine receptor operating as a decoy and scavenger receptor for most inflammatory CC chemokines, and its role in the control of inflammatory responses is well established (3, 5). D6-deficient mice have been reported to have increased susceptibility to skin carcinogenesis (6) and colitis-associated cancer (7), thus providing genetic evidence of a nonredundant function of inflammatory chemokines in tumor biology (8–11). D6 is selectively expressed in lymphatic endothelial cells (LEC) and in a subset of vascular tumors (12), but its role in these malignancies is unknown.

Kaposi sarcoma (KS) is a vascular tumor caused by the infection of LECs by the human herpes virus 8 (HHV8). KS tumor cells, also referred to as spindle cells for their shape, are considered to be derived from the LEC lineage and express several LEC markers, including VEGFR3, LYVE-1, and PROX1 (13). It has been shown that KS can also derive from HHV8-infected blood vascular cells that undergo a lymphatic reprogramming to create a more favorable microenvironment for tumor growth (14). Even though HHV8 infection is widespread, KS occurs only sporadically in immunocompetent individuals as classical KS, which is usually characterized by slow-progressing skin lesions with limited dissemination ability. However, KS is relatively common in immunocompromized patients; it displays a more aggressive phenotype with widespread diffusion on the skin, frequent involvement of visceral organs, and life-threatening complications (15). As current therapeutic options are only palliative, KS is a leading cause of morbidity and mortality in patients with AIDS (16, 17).

KS lesions appear as multiple foci highly heterogeneous in their composition depending on the disease stage. The first lesions detectable in the dermis, called patch lesions, are...
composed of a few HHV8-infected spindle cells, an abundant inflammatory infiltrate mainly containing T and B lymphocytes and monocytes, and a prominent angiogenic process. Then lesions progress to the plaque stage, characterized by lesions that are solid, edematous, and violaceous in color, and finally to maculonodular lesions, with abundant abnormal leaky vessels with edema and erythrocyte extravasation and a predominance of spindle cells (18). KS lesions are classified in four clinical stages (I, maculonodular lesions; II, infiltrative; III, florid; and IV, disseminated). Lesions at the same stage show a highly variable progression rate and are further subdivided retrospectively according to the speed of disease evolution (A, slow progressive lesions, and B, rapid progressive lesions; ref. 19).

Spindle cells do not display some characteristics of transformed cells, being euploid and not clonal, and with a growth potential in vitro and in vivo largely dependent on the auto- crine/paracrine activity of angiogenic and inflammatory cytokines, including VEGF-A, basic fibroblast growth factor 2 (bFGF2), interleukin (IL)-6, and IL-1β (15, 20). It has been proposed that spindle cells produce cytokines that recruit leukocytes and vessels, which in turn produce growth factors required for their proliferation (18, 21, 22). Consistent with this, KS lesions often occur at inflammatory sites or in scarring tissues, a condition known as Koebner phenomenon, and in patients with the immune reconstitution inflammatory syndrome (23). Among inflammatory mediators, chemokines have been investigated extensively in KS pathogenesis because HHV8 has hijacked the chemokine system in several ways (24). HHV8 encodes a constitutively active GPCR, recognizing both angiostatic, i.e., without the Glu-Leu-Arg amino acid motif (ELR-) and angiogenic ELR+ CXC chemokines, which act as transforming receptors in transgenic mice (25), and three CC chemokines (vMIP-I, -II, and -III) that interact with the CCR3, CCR8, and CCR4 receptors that are expressed at high levels in Th2 and regulatory T cells (Treg; refs. 26, 27); these viral inflammatory CC chemokines represent a strategy to subvert and divert effective antiviral and antitumor immunity. In addition, HHV8-infected endothelial cells display increased production of several chemokines, including CCL2, CCL5, CXCL8, and CXCL16 (28, 29).

Considering the lymphatic origin of KS and the relevance of the chemokine system in its biology, we investigated the expression and the role of the atypical chemokine receptor D6 in this tumor.

Materials and Methods

**Immunohistochemistry**

Formalin-fixed paraffin-embedded cutaneous nodular KS lesions from HIV-seropositive and -seronegative cases were obtained from Luigi Sacco Hospital and Ospedale Maggiore Policlinico (Milan, Italy), respectively. Cutaneous nodular KS lesions from HIV-seronegative patients were classified according to a staging system (19) comprising four clinical stages (I, maculonodular lesions; II, infiltrative; III, florid; and IV, disseminated), each further divided according to the speed of disease evolution (A, slow, and B, rapid). Ethics approval for D6 expression analysis was obtained from the local Institutional Review Committee, and a signed informed consent was obtained from all participants. Sections were incubated with rat anti-human D6 monoclonal antibody (mAb; clone 196124, 1:100 dilution; R&D Systems) and mouse anti-human KSHV Orf73 mAb (1:100 dilution; Dako). For murine tumors, frozen sections were incubated with rat anti-mouse CD31 mAb (1:100 dilution; obtained as described in ref. 30).

**Cell culture and transfection**

The KS-IMM cell line, originally isolated from a KS from a kidney-transplanted immunosuppressed patient (31), was grown in Dulbecco’s Modified Eagle Medium (DMEM; Lonza) with 10% fetal calf serum (FCS). KS-IMM cells were transfected with the hD6/pEFGP-N1 or empty pEFGP-N1 expression plasmids by using Lipofectamine 2000 (Invitrogen) and selected using 400 μg/mL G418 (Invitrogen). For growth curve, KS-IMM cells were seeded in 6-well plates (5 × 10⁴ cells/well) and grown under normal conditions for 1 to 4 days. Every day, cells were harvested with trypsin from 3 wells per group, diluted in Trypan blue to assess viability, and counted. For the preparation of cell culture supernatant, KS-IMM cells (1 × 10⁶ cells) were cultured in 75-cm² flasks with complete medium. After 48 hours, culture medium was discarded, and fresh medium without G418 was added to the flask for 24 hours. Supernatant was collected and centrifuged.

**Immunofluorescence microscopy analysis**

KS-IMM cells (10⁴) were seeded in 24-well plates and grown at 37°C for 18 hours. Cells were fixed with 4% paraformaldehyde and then incubated with 4,6-diamidino-2-phenylindole (DAPI). High-resolution images (1,024 × 1,024 pixels) were acquired sequentially with a 60×/1.4 NA Plan-Apochromat oil immersion objective using a FV1000 laser scanning confocal microscope (Olympus). Differential interference contrast (Nomarski technique) was also used. Images were assembled and cropped using Photoshop software (Adobe Systems).

**Reverse transcriptase PCR**

Total RNA was extracted from cell pellets using the TRIzol reagent (Invitrogen). The reverse transcriptase PCR (RT-PCR) was performed using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer’s instructions with primers for human D6 (forward: 5’-GGGTGTCTTCTTCACACTCT-3’; reverse: 5’-TATTTCCCAACTCCCTAG-3’) and human β-actin (forward: 5’-GCTGTCGACAAAGGCT-3’; reverse: 5’-CAACATGATCTGGGGTACTCCTTGC-3’). TaqMan real-time RT-PCR was used to detect D6 RNA in KS-IMM seeded in DMEM 1% FCS overnight and stimulated for 8 or 24 hours with U0126 (10 μmol/L; Calbiochem) and PLX4032 (1 μmol/L; Selleckchem).

**Chemokine scavenging assay**

KS-IMM transfectants were plated the day before the experiment in 96-well plates (3 × 10⁴ cells/well), and then incubated with 10 ng/mL of CCL3L1 (R&D Systems) for increasing times. The supernatant was collected and the chemokine concentration was evaluated by sandwich ELISA (R&D Systems).
Bone marrow–derived macrophages

Bone marrow macrophages were obtained from femurs of 8-week-old male wild-type (WT) and CCR2−/− C57/B6 mice and plated in DMEM with 5% FCS for 4 hours at 37°C. Nonadherent cells were recovered and plated at 3 × 10^5 cells per well in 24-well ultra-low attachment plates (Corning Costar) and cultured for 7 days in the presence of 25% conditioned media from D6+ KS or D6− KS cells or with 20 mg/mL murine macrophage (mM)-colony-stimulating factor (mM-CSF; Miltenyi Biotec) added every 2 days. When indicated, indomethacin (Sigma) was added to cultures at 10 μmol/L from day 0. After 7 days, cells were detached with cold Accutase (Millipore).

In vivo experiments

WT and CCR2−/− C57/B6 mice and nude CD-1 mice were purchased from The Jackson Laboratory and Charles River Italia, respectively. Animals were housed in pathogen-free conditions, and used at 8 to 12 weeks of age. Mice were injected subcutaneously in the flank with 5 × 10^6 KS-IMM cells mixed with liquid Matrigel (BD Biosciences). The two major tumor diameters were measured every 2 to 3 days with a caliper, and the tumor volume was estimated by applying the formula (d1 × d2^2)/2. To deplete neutrophils in vivo, purified anti-Ly6G rat mAb (clone 1A8; BioXcell) was administered to mice (intraperitoneally; 0.2 mg) 1 day before KS-IMM inoculation and every 3 days thereafter. Control animals were injected with purified rat immunoglobulin G2a (IgG2a; BioXcell). Pharmacologic inhibition of CCR2 was achieved by treating mice daily with 2 mg/kg RS-504393 (Santa Cruz Biotechnology) via oral gavage from the day of KS-IMM injection until the day the animals were sacrificed. In some experiments, bone marrow–derived macrophages (BMDM; 10 ng/mL mM-CSF) generated from WT and CCR2−/− C57/B6 mice were mixed in liquid Matrigel at 1:2 ratio with KS-IMM cells and subcutaneously injected. Animal housing and procedures were in accordance with national (D.L. N.116, reviewed and approved Gazzetta Ufficiale della Repubblica Italiana, supplement 40, 18-2-1992) and international law and policies (European Economic Community Council, 1987, Directive 86/609, Official Journal of European Community L358;1 and Institute of Laboratory Animal Resources, Committee on Life Sciences, National Research Council, 1996, Guide for the Care and Use of Laboratory Animals). Animal procedures were also reviewed and approved by the Institutional Ethical Committee at Humaitas Clinical and Research Center (Rozzano, Italy).

Fluorescence-activated cell sorting analysis and sorting

Flow cytometry was performed using FACSCanto II flow cytometer and FACSDiva 6.1.1 software (BD Biosciences) or FlowJo (TreeStar). KS-IMM cells were sorted for enhanced GFP (EGFP) expression by using a FACSAria cytometer and FACSDiva 6.1.1 software (BD Biosciences) or a FACSAria II flow cytometer (BD Biosciences). For tumor infiltration analysis, tumor explants were harvested at the indicated time points, minced and incubated in DMEM with 1% FCS plus collagenase IV (Sigma-Aldrich Chemicals) for 30 minutes at 37°C, and then passed through a 70-μm nylon mesh filter (BD Falcon). Erythrocytes were lysed with ammonium–chloride–potassium buffer. Cells were stained with anti-mouse CD45–PerCP, CD11b–APC, Ly6G–PE, Ly6C–FITC, I-A/I-E–Biotin, anti-CD206–Biotin (BD Biosciences), and F4/80 (S erotec). Dead cells were excluded by the LIVE/DEAD Fixable Cell Stain Kit (Invitrogen). The absolute number was determined using TruCount beads (BD Biosciences) according to the manufacturer’s instructions.

Cytokine levels and migration assay

KS-IMM cells were seeded into 24-well microplates (9 × 10^5 cells/well) and grown under normal conditions for 24 hours. The medium was replaced by DMEM with 1% FCS, and in a particular experiment 10 ng/mL of human IL-1β (R&D Systems) were added. Supernatants were collected after 24 hours and hCCl2, hIL-6, and hVEGF-A were measured using sandwich ELISA (R&D Systems). mVEGF-A was measured in tumor lysates and BMDM supernatants using ELISA test (R&D Systems) and murine chemokines using Bio-Plex protein assay (Bio-Rad). Human monocyte isolation and migration toward D6+ KS or D6− KS tumor-conditioned medium (TCM) were performed as previously described (32).

Western blot analysis

Cells (0.7 × 10^7) were treated as indicated and lysed with a buffer containing 50 mMol/L Tris–HCl (pH 8), 150 mMol/L NaCl, 5 mMol/L EDTA, 1.5 mMol/L MgCl₂, 10% glycerol, 1% Triton X-100, and protease/phosphatase inhibitors. The lysates were electrophoresed and immunoblotted with the rabbit anti-human ph-ERK1/2 antibody (Cell Signaling Technology) under standard conditions. Chemiluminescence was acquired by the ChemiDoc XRS Imaging System, densitometric analysis was performed by Image Lab software (Bio-Rad), and the protein band intensity was calculated by normalizing against the α-tubulin band intensity.

Statistical analysis

Data were compared using an unpaired Student t test. Immunohistochemical data were analyzed by the two-tailed unpaired t test with Welch correction (GraphPad Prism4 software). * P < 0.05; ** P < 0.005; *** P < 0.0005. Linear regression analysis was obtained using Prism4 software.

Results

D6 is expressed in KS lesions

D6 was reported to be expressed by LECs (12), which are precursors of KS spindle cells (13); we investigated D6 expression in KS lesions. D6 expression was readily detectable in indolent cutaneous nodular lesions of HIV-seronegative patients and, to significantly lower levels, in aggressive lesions in HIV-seropositive patients (Fig. 1A). When biopsies of maculonodular lesions of HIV-seronegative patients were analyzed, D6 expression was significantly higher in patients who showed a slow disease progression rate (stage IA) than in those characterized by a rapid progression rate (stage IB; Fig. 1B; ref. 19). D6 staining was observed in a large fraction of spindle-shaped tumor cells, which were also positive for the HHV8-encoded nuclear antigen LAN-1 (Fig. 1C).

D6 expression restraints KS growth in vivo

To determine the role of D6 in KS, we used the human cell line KS-IMM, originally derived from a biopsy of an iatrogenic...
KS that was able to grow in nude mice as highly vascularized tumors closely resembling human KS lesions (31). As KS-IMM cells were negative for D6 expression (Supplementary Fig. S1A), their expression was reconstituted by transfection. D6 expression in D6⁺ KS was confirmed by RT-PCR (Supplementary Fig. S1A) and fluorescence microscopy (Supplementary Fig. S1B), which also showed predominant localization of D6 in intracellular perinuclear compartments, consistent with the distribution of D6 observed in KS spindle cells (Fig. 1C) and other D6 transfectants (33). D6 was functional, as D6⁺ KS but not D6⁻ KS cells internalized and degraded exogenously provided chemokines (Supplementary Fig. S1C). D6⁺ KS supernatant contained higher levels of hCCL2 (Supplementary Fig. S1F) and exhibited higher chemotactic activity for monocytes as compared with D6⁻ KS supernatant (Supplementary Fig. S1G), indicating that D6 expression affected the chemotactic potential of KS cells. Consistent with the D6 specificity for chemokines, no difference was found in the amount of IL-6 and VEGF-A detected in the supernatant of D6⁺ KS and D6⁻ KS cells (Supplementary Fig. S1D and S1E, respectively). Finally, no difference was found in the growth rate of D6⁺ KS and D6⁻ KS cells (Supplementary Fig. S1F). D6-transfected KS-IMM cells express a fully functional D6 scavenger receptor, which has an impact on the chemokine milieu but not on the production of other cytokines or on cell growth in vitro.

The role of D6 in vivo was investigated by implanting three independent populations of D6⁺ KS and D6⁻ KS cells in the flanks of CD-1 nude mice (Fig. 2A and B, respectively). Up to day 19 after injection, the two groups of animals showed comparable tumor uptake and similar tumor growth. However, from day 19 onward, D6⁺ KS tumors were significantly larger than D6⁻ KS tumors and, at the conclusion of the experiment, they were on average 2.77 ± 1.28 times bigger than D6⁻ KS tumors, suggesting that the lack of D6 expression allows an increased tumor growth rate in vivo (Fig. 2C). An analysis of the necrotic area at this time point by hematoxylin and eosin staining showed no difference between D6⁺ KS and D6⁻ KS tumors (Supplementary Fig. S2), indicating that the greater tumor size of D6⁺ KS was not due to higher necrosis, as previously reported for other atypical chemokine receptors (34).

**Higher levels of inflammatory chemokines and M2-like tumor-associated macrophages infiltrate in D6⁺ KS**

To dissect the mechanism by which D6 restrains KS growth in vivo, lysates of D6⁺ KS and D6⁻ KS tumors were analyzed for their chemokine content. When compared with D6⁺ KS lysates, D6⁻ KS lysates contained a higher amount of host-derived mCCL2, mCCL5, and mCCL3 (Fig. 3A–C, respectively). Very low concentrations of hCCL2 were detected (data not shown), indicating that the main source of chemokines in the system was infiltrating host cells rather than tumor cells, as reported for some human tumors (11).

When the explanted tumors were analyzed for their cellular composition by flow cytometry analysis, tumor masses were...
Downregulation of D6 Expression in Kaposi Sarcoma

Figure 2. D6 expression restrains KS tumor growth in vivo. A and B, growth rate of tumors generated in the flank of each CD-1 nude mouse injected with $5 \times 10^6$ D6 KS (n = 23) or D6 KS (n = 17) cells, respectively. C, average volumes $\pm$ SEM of tumors derived from D6 KS (□) and D6 KS (■). Representative tumor explants derived from D6 KS (top) and D6 KS (bottom) are shown on the side. ***, $P < 0.0005$.

composed of equal amounts of tumor cells (EGFP$^+$ and CD45$^-$) and infiltrating leukocytes (EGFP$^-$/CD45$^+$). Stromal cells (EGFP$^-$/CD45$^+$) represented less than 5% of the tumor mass (Fig. 3D). Expression of D6 not only had a significant impact on the number of tumor cells and infiltrating leukocytes (Fig. 3E and F), but it also had qualitative effects on the infiltrating leukocytes. In the absence of D6, KS tumors showed a significant increase in infiltrating neutrophils (CD11b$^+$, Ly6C$^{int}$, F4/80$^-$, and Ly6G$^+$; Fig. 3G) and tumor-associated macrophages (TAM; R3: CD11b$^+$, Ly6C$^+$, F4/80$^+$; Fig. 3H), while they contained a reduced number of monocytes (R1, CD11b$^+$, Ly6C$^{high}$, and F4/80$^-$; R2, CD11b$^+$, Ly6C$^{high}$, and F4/80$^-$). TAMs were then analyzed for the expression of the M1 marker MHC-II and the M2 marker mannose receptor (also known as CD206). Compared with D6$^+$ KS, TAMs infiltrating D6$^-$ KS tumors had decreased levels of MHC-II and a tendency to have more CD206 (Fig. 3I and J, respectively). Similar results were obtained with BMDM differentiated in vitro with TCM from D6$^+$ KS or D6$^+$ KS, with a higher amount/percentage of macrophages (Fig. 4A), increased levels of the M2 marker CD206 (Fig. 4C), and reduced levels of the M1 marker MHC-II (Fig. 4B) induced by TCM from D6$^+$ KS as compared with TCM from D6$^+$ KS cells. These data indicate that reduced levels of D6 are associated with increased TAM recruitment and their local maturation toward M2-like polarization.

TAM recruitment is required for KS growth

To assess the role of the tumor-infiltrating leukocytes on KS growth, depletion experiments were performed. Treatment with the anti-Ly6G IA8 mAb efficiently depleted circulating polymorphonuclear leukocytes (PMN; Fig. 5A) and abolished their infiltration in KS tumors (Fig. 5B), but had no effect on the progression of both D6-competent and -incompetent tumors (Fig. 5C). Conversely, the reduction of circulating monocytes (Fig. 5D) and infiltrating TAMs (Fig. 5E) by treatment with the CCR2 antagonist R5-50493 had no effect on D6$^+$ KS growth, but it significantly inhibited D6$^-$ KS growth rate at early time points (Fig. 5F). A partial inhibition of the growth of D6$^+$ KS by a CCR2 antagonist is consistent with these lesions containing increased levels of other monocyte-attracting chemokines (Fig. 3B and C). Finally, in vivo experiments showed that while coinjection of WT or CCR2$^{−/−}$ BMDM did not modify D6$^-$ KS tumor growth (Fig. 5G), the growth of D6$^+$ KS tumors was supported by the coinjection of WT but not CCR2$^{−/−}$ BMDM (Fig. 5H), indicating the relevance of CCR2 expression by TAMs for their protumor activity beyond their local recruitment.

Increased production of VEGF-A and angiogenesis in D6$^-$ KS

To understand the mechanism by which TAMs promote KS growth, the content of the angiogenic factor VEGF-A and the expression of the endothelial cell marker CD31 in D6$^+$ KS and D6$^-$ KS tumor sections were investigated. Although no difference was found for the human VEGF-A content (data not shown), D6-competent tumors showed higher levels of murine VEGF-A than D6-competent tumors (Fig. 6B), and immunohistochemical analysis with anti-CD31 showed that D6$^+$ KS cells were more vascularized than D6$^-$ KS (Fig. 6A). The conditioned medium of D6$^+$ KS but not D6$^-$ KS cells increased the production of mVEGF-A by BMDM (Fig. 6C). This effect was not observed when CCR2$^{−/−}$ BMDMs were used (Fig. 6C), indicating a key role for tumor-derived CCR2 agonists in the acquisition of a proangiogenic phenotype. CCR2 agonists were described to induce VEGF-A production through an autocrine pathway requiring COX2 activity (35, 36). In agreement with this observation, the COX2 inhibitor indomethacin inhibited mVEGF-A production by BMDM stimulated with D6$^+$ KS TCM (Fig. 6C).

Role of the ERK pathway in the downregulation of D6 expression

The HHV8 reactivation process in KS is associated with the activation of the K-Ras–B-Raf–MEK pathway (37), and the K-Ras–activating mutations or amplifications are frequently found in KS lesions, particularly in the advanced stages (38, 39). To investigate the connection between ERK pathway activation and D6 downregulation, we analyzed the KS-IMM cell line. Although no mutations in the K-Ras gene were detected, the B-Raf V600E oncogenic mutation was present (Fig. 7A). Consistent with the ability of activated B-Raf to phosphorylate MEK, which in turn activates the ERK1/2 pathway (40), KS-IMM showed high levels of ERK1/2 phosphorylation (Fig. 7B), which was inhibited by
Figure 3. Increased chemokine content and leukocyte infiltrate in D6-negative tumors. (A) mCCL2, (B) mCCL5, and (C) mCCL3 were measured in homogenized tumors at day 14 after inoculation. Data are expressed as the mean concentration ± SEM of the chemokine levels normalized for the tumor volume (n = 4/group). D, representative dot plot analysis of an enzymatically digested tumor stained and analyzed by flow cytometry showing gating strategy to detect tumor cells (KS) and tumor-infiltrating leukocytes (TIL) analyzing live cells and singlets in single-cell suspension for the expression of GFP and CD45. Mean ± SEM of the total number of GFP+ KS cells (E) and CD45+ infiltrating leukocytes (F) at day 7 and 14 after inoculation of D6+ KS (■) and D6- KS (□) are shown. G, representative dot plot and mean of the percentage of CD11b+ Ly6G+ neutrophils in the CD45+ (H) gate and monocytes (R1, Ly6C+ and F4/80-), mono-macrophages (R2, Ly6C+ and F4/80+), and macrophages (R3, Ly6C- and F4/80+) in the CD11b+ Ly6G- gate at day 7. Representative histogram plot and mean fluorescence intensity (MFI) of (I) MHC-II and (J) CD206 expression of R3-gated cells in D6+ (black line) and D6- KS (gray area) tumors. All gates are based on isotype controls. In all figures histograms represent the mean ± SEM of at least three independent experiments (n = 5 tumors/group) of D6+ KS (black bar) or D6- KS (white bar). *, P < 0.05; **, P < 0.005.
the B-Raf inhibitor PLX4032 and the MEK inhibitor U0126 with a concomitant upregulation of D6 expression (Fig. 7C), indicating that D6 expression in KS-IMM is downregulated as a consequence of the constitutive activation of the B-Raf–MEK–ERK pathway.

ERK activation, macrophage infiltration, and D6 expression in human KS

To assess the actual clinical relevance of the pathway described above, ERK1/2 activation, D6 expression, and macrophage infiltration were examined in a series of patients with KS. In KS spindle cells of stage IB KS lesions, an inverse correlation was observed between ERK1/2 activation (anti-pERK staining) and D6 expression (n = 10; Fig. 7D; Supplementary Fig. S3). Immunohistochemical analysis showed increased infiltration of CD68+ and CD163+ (Fig. 7E and Supplementary Fig. S3) macrophages in KS lesions characterized by a rapid progression rate (stage IB) as compared with slow progressing ones (stage IA), and in these lesions there was also a significant inverse correlation between D6 expression levels and the number of CD68+ (P = 0.039; n = 18) and CD163+ cells (P = 0.003; n = 18; Fig. 7F). Taken together, these results are consistent with data obtained in the experimental model using the KS-IMM cell line and support the notion that in KS progression, activation of the B-Raf–MEK–ERK pathway mediates the downregulation of D6, resulting in increased chemokine-mediated infiltration of TAM and their local activation toward a tumor-promoting M2-like phenotype.

Discussion

Chemokines are important components of cancer-related inflammation affecting tumor progression in multiple pathways, including tumor cell proliferation and survival, invasion and metastasis, leukocyte recruitment, and angiogenesis (3, 8, 41). By targeting the degradation of most inflammatory CC chemokines and limiting their bioavailability in tissues, the atypical chemokine receptor D6 represents an emerging mechanism of regulation of the chemokine system (42). D6 has a well-established nonredundant role in the control of the inflammatory response, regulating the traffic and the activity of cells of the mononuclear system, in particular inflammatory monocytes (5), and also a negative role in inflammation-driven tumor development in experimental models (6, 7). D6 has been reported to be expressed in human choriocarcinoma cell lines (43) and in breast (44) and vascular tumors (12, 45), but its actual relevance in human cancer has not been established.

KS is a malignancy caused by the interplay of the HHV8-infected LECs, oncogenic events, and a tumor-promoting chronic inflammatory milieu (22). Considering the major role of inflammatory chemokines in KS pathogenesis and that LECs express the atypical chemokine receptor D6 (14), analysis of its expression was performed on biopsies of KS lesions. D6 was found expressed by HHV8-infected spindle-shaped KS cells, and its expression was inversely correlated with tumor aggressiveness, both when comparing maculonodular KS lesions retrospectively classified according to their progression rate (group A vs. group B stage I lesions) and when comparing maculonodular lesions of HIV-seronegative and HIV-seropositive patients, who typically show a slow and rapid progression rate, respectively.

To test the hypothesis emerging from these observations that the reduction of D6 expression might be part of the natural KS progression process, we set up an experimental model based on the tumor cell line KS-IMM, which was derived from a human
KS lesion and induces KS-like sarcomas, retaining most features of the parental tumor when injected subcutaneously into nude mice (31). When compared with D6-expressing KS, D6-incompetent KS displays increased tumor growth in vivo but not in vitro, suggesting that D6 expression may influence KS growth by interfering with the tumor microenvironment. Consistent with this observation, D6-negative tumors were found to be characterized by increased levels of inflammatory chemokines and profound changes in the intratumoral leukocytic infiltrate composition. D6-negative tumors showed an increased infiltration of TAMs and tumor-associated neutrophils. Despite the fact that tumor-associated neutrophils have been reported to be important for tumor growth by activating angiogenic factors (46), the selective depletion of Ly6G⁺ cells did not affect KS growth. Conversely, inhibition of monocyte recruitment and TAM infiltration by the use of a CCR2 antagonist inhibited the growth rate of D6⁺ KS tumors. Direct assessment of the requirement of TAMs for KS growth was demonstrated by adoptive transfer experiments showing that coinjection of BMDM promoted D6⁺ KS growth. D6 expression downregulation (in

Figure 5. KS growth is sustained by TAM recruitment. Mice inoculated with D6⁺ KS or D6⁻ KS cells were treated with a blocking antibody against Ly6G (1A8) or the specific CCR2 antagonist RS-509343 (RS). Representative dot plot analysis at day 25 of (A) circulating and (B) tumor-associated PMN (CD11b⁻ and Ly6G⁺) from D6⁺ KS-bearing mice before and after 1A8 treatment. The graph shows the percentage ± SEM of PMN in D6⁺ KS tumors. C, D6⁺ (solid line) and D6⁻ KS (dashed line) tumor volume after subcutaneous inoculation in PBS or 1A8-treated mice. D, representative flow cytometry gating scheme at day 25 of circulating monocytes (CD11b⁺ and CD115⁺). E, CD11b⁺ Ly6G⁺ tumor infiltrate in PBS-treated versus RS-treated D6⁺ KS tumors. The monocyte-macrophage population was gated as described in Fig. 3H and number ± SEM is shown in the graph. F, D6⁺ KS (solid line) and D6⁻ KS (dashed line) tumor volumes after treatment with PBS (■) or RS (■). G and H, tumor growth of D6⁺ KS and D6⁻ KS, respectively, injected alone (■) or with WT (■, dotted line) or CCR2⁻/⁻ BMDM (■, solid line). In all panels, data are representative of two independent experiments (n = 8 mice/group). Results are expressed as mean ± SEM. *, P < 0.05; ***, P < 0.0005, D6⁺ versus D6⁻ KS; #, P < 0.05 treatment versus control.
time points. Data are expressed as the mean from five random fields for each sample. Representative images of mCD31 immunohistochemical analysis in D6+/KS and D6−/KS tumors at day 7 after implantation are shown (magnification, ×20). B, mVEGF-A concentration in homogenized D6+/KS and D6−/KS tumors at indicated time points. Data are expressed as the mean ± SEM (n = 4/group) normalized for the tumor volume. C, mVEGF-A production by WT and CCR2−/BMDM stimulated for 6 days with D6+ KS or D6− KS TCM or with normal medium (■) and where indicated with indomethacin. Mean ± SEM of at least three independent experiments is shown. Results are expressed as mean ± SEM. *, P < 0.05; **, P < 0.005; †††, P < 0.001.

To tumors other than KS that are characterized by elevated CCL2 levels, including breast and prostate tumors (11).

Oncogenic mutations or amplifications interfering with the K-Ras–B-Raf–MEK–ERK1/2 pathway are frequently observed in late-nodular KS lesions and angiosarcomas (38, 50), where its activity has been shown to support enhanced expression of growth factors and cytokines, including VEGF-A (51). Therefore, we focused on this pathway to elucidate the molecular basis responsible for D6 downregulation associated with tumor progression. Consistently with their aggressiveness in vivo, the KS-IMM cell line, originally established from an advanced KS lesion, harbors an activating oncogenic mutation in the B-Raf gene and shows high levels of constitutive ERK1/2 activity. In this cell system, D6 expression was found to be under the control of this signaling pathway, as its inhibition by either B-Raf or ERK inhibitors resulted in the upregulation of D6. This functional link was then confirmed in KS lesions, where D6 expression levels were found to be inversely correlated with tumor aggressiveness. ERK1/2 activation, and the number of infiltrating TAMs, for which the number and M2-like phenotype were directly correlated with tumor aggressiveness.

The results presented here suggest that during KS progression, oncogenic events activate the ERK1/2 pathway, which induces D6 downregulation in tumor cells. This allows tumor-derived inflammatory chemokines, and in particular CCR2 ligands, to recruit monocytes and sustain their local polarization toward M2-like TAMs, which support a VEGF-A–dependent angiogenic

Figure 6. CCR2+ TAMs sustain angiogenesis in D6+ KS tumors. A, mean ± SEM of the number of CD31+ cells (semiquantitative score: 0, no positive cells; 1, 0%–20% positive cells; 2, 20%–40% positive cells; 3, 40%–60% positive cells; 4, 60%–80% positive cells; and 5, >80% positive cells). Score was given as the mean from five random fields for each sample. Representative images of mCD31 immunohistochemical analysis in D6+ KS and D6− KS tumors at day 7 after implantation are shown (magnification, ×20). B, mVEGF-A concentration in homogenized D6+ KS (■) and D6− KS (□) tumors at indicated time points. Data are expressed as the mean ± SEM (n = 4/group) normalized for the tumor volume. C, mVEGF-A production by WT and CCR2−/BMDM stimulated for 6 days with D6+ KS (■) or D6− KS (□) TCM or with normal medium (■) and where indicated with indomethacin. Mean ± SEM of at least three independent experiments is shown. Results are expressed as mean ± SEM. *, P < 0.05; **, P < 0.005; †††, P < 0.001.

Several studies have indicated that TAMs have a pivotal role in the regulation of tumor angiogenesis, especially at early stages of tumor progression (48). Here, we report that D6-incompetent tumors, in addition to having more TAM, had increased amounts of VEGF-A and intratumoral angiogenesis. Using KS–conditioned media, it was found that increased VEGF-A production by BMDM required CCR2 expression and an autocrine loop triggered by CCR2 agonists involving the induction of COX2 and PGE2 production (35, 36). Furthermore, the requirement of CCR2 expression on macrophages for KS growth was directly demonstrated by adoptive transfer experiments, in which WT but not CCR2−/− BMDMs were able to sustain KS tumor growth. Several studies have correlated CCR2+ TAM infiltration with increased tumor angiogenesis and VEGF-A production (49), but the direct role of this chemokine receptor in the production of VEGF-A has not been assessed. In addition to its known chemotactic function, we have provided evidence that CCL2 can also directly affect the angiogenic potential of TAMs; these results may be relevant...
switch promoting tumor growth. Targeting these components of the KS tumor microenvironment may represent alternative or complementary therapeutic strategies.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: B. Savino, N. Caronni, R. Bonecchi

References

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): N. Caronni, F. Pasqualini, A. Tourlaki

Study supervision: G. Vago, A. Mantovani, M. Locati, R. Bonecchi

Acknowledgments
The authors thank Dr. Adriana Albini (IRCCS Multimedica, Science and Technology Pole, Milan, Italy) for providing the KS-IMM cell line.

Grant Support
Research activities in the laboratory are supported by Ministero dell’Istruzione dell’Università e della Ricerca (PRIN and FISR projects), Ministero della Salute (Ricerca Finalizzata), the Italian Association for Cancer Research (ARCI), and the European Community’s Seventh Framework Programme [FP7-2007-2013] under grant agreement HEALTH-F4-2011-281608 (TIMER).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 13, 2013; revised February 17, 2014; accepted March 2, 2014; published OnlineFirst April 2, 2014.
Downregulation of D6 Expression in Kaposi Sarcoma


Receptor D6 Drives Tumor Aggressiveness in Kaposi Sarcoma

Benedetta Savino, Nicoletta Caronni, Achille Anselmo, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/2326-6066.CIR-13-0202

Supplementary Material
Access the most recent supplemental material at:
http://cancerimmunolres.aacrjournals.org/content/suppl/2014/04/03/2326-6066.CIR-13-0202.DC1

Cited articles
This article cites 50 articles, 17 of which you can access for free at:
http://cancerimmunolres.aacrjournals.org/content/2/7/679.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://cancerimmunolres.aacrjournals.org/content/2/7/679.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link:
http://cancerimmunolres.aacrjournals.org/content/2/7/679.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.